Dementia experts from UC San Francisco will join their peers from around the globe at the annual Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston from Oct. 24 to 27.
Presentations cover breakthroughs in therapies that clear amyloid – a hallmark of Alzheimer's – and a symposium on patients with early Alzheimer's symptoms who were treated with the anti-amyloid medication donanemab, which may be approved by the end of the year. Other topics include novel treatments, diagnostic blood biomarkers, amyloid-related imaging abnormalities and Medicare coverage.
CTAD brings together leaders from academic research centers, patient advocacy groups, international research coalitions and pharmaceutical companies.• Charles Windon, MD, will present Race and Sex Effects on Rates of Amyloid-Positivity in Real-World Memory Care. Using data from 17,000 participants enrolled in the IDEAS study, Windon and colleagues looked at PET scans in female and African American, Latino and Asian individuals, to evaluate ethnocultural and sex differences in amyloid rates.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Diversity among research staff found to increase participation of underrepresented patients in clinical studiesNew research from Boston Medical Center found that research staff who interact with patients of the same race or ethnicity increased the odds of those patients agreeing to participate in clinical studies by almost a factor of 3.
Read more »
Cancer drug that targets two immune-evading tumor tactics performs well in early clinical trialA 'two-for-one' cancer immunotherapy is potentially more effective and at least as safe as standard immunotherapies, physician-scientists from UPMC Hillman Cancer Center who led an international, early-phase clinical trial report in the journal Nature Medicine.
Read more »
National ICU registries as enablers of clinical research and quality improvementClinical quality registries (CQRs) have been implemented worldwide by several medical specialties aiming to generate a better characterization of epidemiology, treatments, and outcomes of patients.
Read more »
Study highlight potential links between COVID-19 and Alzheimer's diseaseThe various neurological symptoms that patients with COVID-19 have experienced suggest that viral infections may increase the risk of neurodegeneration, which could in turn contribute to the development of conditions such as Alzheimer's disease (AD).
Read more »
Banbury Michaelmas street fair trials extra dayThe annual event sees fairground rides, games and food stalls along Broad Street.
Read more »
Q&A: Validating an MRI biomarker for early onset Alzheimer's diseaseAlexandra Touroutoglou, Ph.D.
Read more »